TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33771763
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12, 10^9 colony-forming units, orally, once daily for 6 months
Study: 37645033
Drug: Aripiprazole as
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole as adjunctive therapy with valproate sodium
Study: 37645033
Drug: Risperidone as
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone as adjunctive therapy with valproate sodium
Study: 34927590
Drug: Wearable activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable activity tracker + 6 weekly behavioral support emails
Study: 616625220
Drug: EOAP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOAP regimen combined with Chansu injection (20 ml/d, intravenous drip, on d 1-14)
Study: 39480221
Drug: Intravenous access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous access
Study: 32022827
Drug: Risk reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk reduction through family therapy (RRFT)
Study: 32454417
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2/day on days 1, 22 and 43 of radiotherapy)
Study: 32454417
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 loading dose, 250 mg/m2/week during radiotherapy)
Study: 35186114
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg/kg before skin incision for 10 min, followed by intravenous infusion at 0.4 µg·kg‐1·h‐1 until 30 min before surgery.
Study: 34672064
Drug: 0.33% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.33% hydrocortisone sodium phosphate solution
Study: 34672064
Drug: 0.001% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.001% hydrocortisone sodium phosphate solution
Study: 35724496
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation (CR) plus treatment-as-usual (TAU)
Study: 35477377
Drug: Low-dose intrathecal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intrathecal morphine (100 µg) with 12.5 mg of 0.5% hyperbaric bupivacaine
Study: 35477377
Drug: Sufentanil PCIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil PCIA (100 µg) with 12.5 mg of 0.5% hyperbaric bupivacaine
Study: 35477377
Drug: Low-dose intrathecal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intrathecal morphine (100 µg)
Study: 35477377
Drug: Sufentanil PCIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil PCIA (100 µg)
Study: 38717038
Drug: Once-weekly somatrogon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly somatrogon (0.66 mg/kg/week)
Study: 38717038
Drug: Once-daily somatropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily somatropin (0.24 mg/kg/week)
Study: 38053515
Drug: Once-weekly somatrogon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly somatrogon
Study: 34476342
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg) plus Vitamin D (400 IU) supplementation
Study: 34476342
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg) plus Vitamin D (400 IU) supplementation with personal supplements
Study: 35316819
Drug: Nerve Growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve Growth Factor (NGF) injection
Study: 32044905
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO, n = 38, 2 g day‐1 EPA + DHA)
Study: 32777896
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (0.1 mg kg–1) administered 20 min before intubation
Study: 35974309
Drug: alfentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil and remimazolam 0.1 mg/kg (AR1 group)
Study: 35974309
Drug: alfentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil and remimazolam 0.15 mg/kg (AR2 group)
Study: 35974309
Drug: alfentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil and remimazolam 0.2 mg/kg (AR3 group)
Study: 34106250
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS under placebo medication
Study: 34106250
Drug: Cathodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal tDCS under placebo medication
Study: 34106250
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS under citalopram (20 mg/40 mg)
Study: 34106250
Drug: Cathodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal tDCS under citalopram (40 mg)
Study: 34106250
Drug: Cathodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal tDCS under citalopram (20 mg)
Study: 33772124
Drug: Active intervention
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intervention group (AG) with multiple interventions including training courses for nurses on dental health, oral health-related information cards (OHICs), and atraumatic restorative treatment (ART)-trained dentists
Study: 33772124
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) receiving a 45-minute lecture on oral health
Study: 34747807
Drug: MIRE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIRE therapy
Study: 32766852
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy for CNS+ patients in the international randomized phase 3 trial Inter-B-NHL-ritux 2010
Study: 33908815
Drug: Luteinising hormone
Normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinising hormone (LH) supplementation (Group A)
Study: 32186587
Drug: Conventional Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Oxygen Therapy
Study: 32876405
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg (group C)
Study: 32876405
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg (group P)
Study: 33977835
Drug: Varied ROM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varied ROM (daily alternation between INITIALROM and FINALROM)
Study: 34478028
Drug: IV milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV milrinone (0.5 µg/kg/min, median duration of infusion 5 days)
Study: 34996347
Drug: WBF-011 (5-strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBF-011 (5-strain novel probiotic formulation)
Study: 35586668
Drug: PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 treatment
Study: 35586668
Drug: PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitor chemotherapy
Study: 32761445
Drug: Oral leukoplakia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leukoplakia cases with etiological factors (smoking, alcohol consumption)
Study: 32617646
Drug: tolcapone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (100 mg TID for 5 days)
Study: 33048154
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (n=153) with 4 weekly, 4 biweekly, and 3 monthly counseling sessions and choice of cessation medication.
Study: 33048154
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=150) with 4 weekly counseling sessions and medication advice.
Study: 33048154
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (n=153) participants reporting cessation medication use.
Study: 33048154
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=150) participants reporting cessation medication use.
Study: 33048154
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group adverse events (n=153).
Study: 33048154
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group adverse events (n=150).
Study: 32441857
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 mg thrice daily)
Study: 35550374
Drug: Intrarectal 10-mg
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal 10-mg diazepam suppository
Study: 32689594
Drug: Rivaroxaban 15mg
Normalized name: RIVAROXABAN 15MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 15mg daily
Study: 32689594
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg daily
Study: 35813411
Drug: Predictive nursing
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive nursing combined with early drinking water therapy
Study: 35729430
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg, n=113)
Study: 35729430
Drug: Glimepiride (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (starting dose: 0.5 mg, n=120)
Study: 33499076
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene board game intervention (60-min sessions, twice a week)
Study: 35176533
Drug: CALAS 20
Normalized name: CALASPARGASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS 20 mg three times daily for seven days
Study: 35176533
Drug: CALAS 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS 40 mg three times daily for seven days
Study: 35176533
Drug: CALAS 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS 80 mg three times daily for seven days
Study: 32781283
Drug: Huoxiang Zhengqi
Normalized name: HYPOCHLOROUS ACID 100 mg in 500 mL EXTRACORPOREAL LIQUID [Huoting slight acid hypochlorite disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules combined with western medicine
Study: 32781283
Drug: Lianhua Qingwen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhua Qingwen granules combined with western medicine
Study: 35435017
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (<2 g of sodium)
Study: 34477291
Drug: Inpatient Treatment-as-Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient Treatment-as-Usual (TAU)
Study: 32894190
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (TA)
Study: 32894190
Drug: Medication (MC)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (MC)
Study: 35175622
Drug: CBD25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD25 (25 mg/kg/day)
Study: 35175622
Drug: CBD50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD50 (50 mg/kg/day)
Study: 36255525
Drug: 0.125% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% levobupivacaine at 8 mL/h
Study: 36255525
Drug: 0.25% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% levobupivacaine at 8 mL/h
Study: 34487151
Drug: Pradefovir 75
Normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradefovir 75 mg
Study: 34488701
Drug: Antipsychotics (AP)
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (AP) withdrawal (pipamperone or risperidone); dose reduced by 25% every 4 weeks.
Study: 34488701
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group); dose remains unaltered.
Study: 32957204
Drug: Conical implants
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical implants
Study: 32957204
Drug: Straight implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straight implants
Study: 34280472
Drug: miR‐185‐5p and
Approvals — FDA: no, EMA: no, PMDA: no
Description: miR‐185‐5p and miR‐425‐5p expression levels measured before radiation therapy
Study: 34280472
Drug: Model including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Model including pretreatment miR‐185‐5p and miR‐425‐5p levels with mean parotid dose
Study: 34280472
Drug: miR‐185‐5p and
Approvals — FDA: no, EMA: no, PMDA: no
Description: miR‐185‐5p and miR‐425‐5p levels after 20 Gy with mean parotid dose
Study: 37748693
Drug: Chemotherapy (platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (platinum-based doublet)
Study: 34269160
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Hold)
Study: 34163141
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tenofovir alafenamide tablets (test formulation)
Study: 32228534
Drug: Health professionals'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health professionals' presentation of treatment arms
Study: 32183810
Drug: Structured drug
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured drug review using the STRIP method assisted by a clinical decision support system (STRIP Assistant, STRIPA) with integrated STOPP/START criteria (version 2)
Study: 32183810
Drug: Structured drug
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured drug review
Study: 32232885
Drug: Consolidated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidated therapy group (CTG) with balneotherapy and Chinese herbal medicine (CHM)
Study: 32232885
Drug: Unconsolidated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconsolidated therapy group (UTG)
Study: 34475270
Drug: Large monthly
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large monthly cash gift
Study: 34475270
Drug: Nominal monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nominal monthly cash gift
Study: 32482669
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy associated with supervised therapeutic exercises (STEP)
Study: 32057962
Drug: 30-min plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-min plasma glucose >182 mg/dl
Study: 34952123
Drug: Quetiapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300 mg/day)
Study: 34952123
Drug: Lithium (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (two different doses)
Study: 34952123
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without lithium
Study: 34154603
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg Capsiate (CAP)
Study: 32757317
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU daily of cholecalciferol
Study: 32757317
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU daily of cholecalciferol (Control)
Study: 35490873
Drug: GDMT titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDMT titrated to achieve NT-proBNP <1000 pg/mL
Study: 32965802
Drug: Low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide (2.5 mg/kg)
Study: 32965802
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (5 mg/kg)
Study: 34984794
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg once daily for 8 days
Study: 33657998
Drug: Mulligan Manual
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulligan Manual Therapy (MMT) and exercise
Study: 35725141
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity promotion text messages
Study: 35725141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1 neutral message related to general health information weekly)
Study: 36111824
Drug: iN2L tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: iN2L tablets and access to Alzheimer's Association supportive programs
Study: 34511168
Drug: Alfacalcidol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (0.25 μg/d) for 4 weeks
Study: 34511168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vitamin C, rutin tablets, dipyridamole, cimetidine, calcium supplements, glucocorticoids)
Study: 32955023
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Acetaminophen + Ibuprofen)
Study: 34010531
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment target (systolic blood pressure <120 mm Hg)
Study: 34010531
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment target (systolic blood pressure <140 mm Hg)
Study: 32621071
Drug: 1064 mg
Normalized name: Aristada 1064 MG in 3.9 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1064 mg q8wk
Study: 32621071
Drug: 882 mg
Normalized name: Aristada 882 MG in 3.2 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 882 mg q6wk
Study: 32621071
Drug: 441 mg
Normalized name: Aristada 441 MG in 1.6 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 441 mg q4wk
Study: 35017008
Drug: Bicalutamide 150mg
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 150mg daily
Study: 33512329
Drug: Therapist-guided, VR-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided, VR-based cognitive training intervention combined with treatment as usual
Study: 33512329
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual without cognitive training
Study: 36228297
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered during the induction of anesthesia
Study: 36506904
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric Carboxymaltose (FCM) 1000 mg IV as a single dose
Study: 36506904
Drug: Ferrous Sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous Sulphate (FS) tablets 120 mg iron daily, taken twice daily
Study: 35869710
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia
Study: 32506827
Drug: TD-0714 (50-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD-0714 (50-600 mg single ascending dose)
Study: 32506827
Drug: TD-0714 (10-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD-0714 (10-200 mg q.d. for 14 days)
Study: 36038614
Drug: Experimental videos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental videos reviewing preparation and administration of medications used during ovarian stimulation
Study: 33666378
Drug: docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel plus curcumin (6 g/d for 7 days every 3 weeks)
Study: 37399894
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 mg orally) plus abiraterone acetate (AAP) (1000 mg/10 mg orally)
Study: 37399894
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 mg orally) plus AAP (1000 mg/10 mg orally)
Study: 32949382
Drug: Practical Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practical Body Image therapy (PBI) with mirror exposure (ME) as an adjuvant to treatment as usual (TAU)
Study: 35218626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupuncture and core muscle training
Study: 36432599
Drug: Oxxynea® (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxxynea® (450 mg)
Study: 32886178
Drug: Intranasal remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal remimazolam (10, 20, and 40 mg)
Study: 32886178
Drug: Intranasal remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal remimazolam solution (higher doses)
Study: 32886178
Drug: Intranasal remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal remimazolam (10 to 40 mg)
Study: 32886178
Drug: Intranasal remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal remimazolam
Study: 32886178
Drug: Intravenous remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous remimazolam (4 mg)
Study: 32885440
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule + placebo of prebiotic
Study: 35758855
Drug: Roselle drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roselle drink (200 ml)
Study: 34121642
Drug: Icelandic yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icelandic yogurt (IR; n 15, 18 g of protein)